Breaking News From Pharma & Bio Ingredients
Inyx To Develop HFA Dose Inhaler
Posted on 2005-11-29 12:22:00
Inyx, Inc. announced today that its wholly owned subsidiary, Inyx Pharma Limited, has been selected by a European pharmaceutical company to develop a combination between a corticosteroid and a beta-2-agonist in a single metered dose inhaler (MDI) utilizing a non-ozone-depleting hydrofluoroalkane (HFA) propellant.
Corticosteroids are the most effective and widely used anti-inflammatory drugs for the treatment of bronchial asthma and other chronic obstructive pulmonary diseases (COPD), such as bronchitis and emphysema. They are often taken with short-acting or long-acting bronchodilators (beta-2-agonists) that are the primary rescue medicine used to treat asthma and other COPD attacks. Today, more and more physicians are prescribing for chronic asthma sufferers combination therapy as a regular drug regimen.
Jack Kachkar, M.D., Chairman and CEO of Inyx, Inc., said, "We are very pleased that Inyx has been selected for this client's important HFA program. This represents Inyx's first combination drug-MDI development work for a client."
Inyx is initially developing test batches in different dosages for the client. This will be followed by stability testing, which is targeted for mid-2006. Commercial production is aimed for 2007.
"Being able to deliver corticosteroid and beta-2-agonist in a single inhaler will not only mean added convenience but also should provide cost savings to consumers because it eliminates the need for buying and carrying two separate inhalers, which should make this a strong competitive product. Moreover, by using a HFA propellant, our client will be able to market this combination therapy throughout Europe," added Dr. Kachkar. The European Union has banned the use of the ozone-depleting CFC (chlorofluorocarbon) propellant in pharmaceutical products, and the U.S. is starting to implement this ban.
Subscribe via RSS
